Legal documents catalogue (cjeu_case)

104,315 documents
30261

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Generics (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-588/16 P.

cjeu_case ·
30262

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Sun Pharmaceutical Industries Ltd and Ranbaxy (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-586/16 P.

cjeu_case ·
30263

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Sun Pharmaceutical Industries Ltd and Ranbaxy (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-586/16 P.

cjeu_case ·
30264

Case C-614/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Merck KGaA v European Commission, Generics (UK) Ltd (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
30265

Case C-611/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Rights of the defence — Reasonable time — Loss of documents due to the passage of time — General duty of care — Regulation (EC) No 1/2003 — Second subparagraph of Article 23(2) — Maximum amount of the fine — Taking into account the business year preceding that in which the European Commission’s decision was adopted — Last full year of normal economic activity)

cjeu_case ·
30266

Case C-601/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Arrow Group ApS, Arrow Generics Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
30267

Case C-591/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — H. Lundbeck A/S, Lundbeck Ltd v European Commission, European Federation of Pharmaceutical Industries and Associations (EFPIA) (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Sales directly or indirectly related to the infringement)

cjeu_case ·
30268

Case C-588/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Generics (UK) Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
30269

Case C-586/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, Ranbaxy (UK) Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
30276

Judgment of the General Court (Second Chamber) of 24 March 2021.#Wirtschaftsgesellschaft des Kfz-Gewerbes mbH v European Union Intellectual Property Office.#EU trade mark – Invalidity proceedings – EU figurative mark representing a fish – Earlier national word mark BLINKA – Relative ground for refusal – No likelihood of confusion – No similarity between the signs – Article 8(1)(b) of Regulation (EU) 2017/1001 – Obligation to state reasons – First sentence of Article 94(1) of Regulation 2017/1001.#Case T-354/20.

cjeu_case ·
30277

Judgment of the General Court (Second Chamber) of 24 March 2021.#Wirtschaftsgesellschaft des Kfz-Gewerbes mbH v European Union Intellectual Property Office.#EU trade mark – Invalidity proceedings – EU figurative mark representing a fish – Earlier national word mark BLINKA – Relative ground for refusal – No likelihood of confusion – No similarity between the signs – Article 8(1)(b) of Regulation (EU) 2017/1001 – Obligation to state reasons – First sentence of Article 94(1) of Regulation 2017/1001.#Case T-354/20.

cjeu_case ·